- Home
- KNSA vs GERN Comparison
KNSA vs GERN Comparison
Compare KNSA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- GERN
- Stock Information
- Founded
- KNSA 2015
- GERN 1990
- Country
- KNSA United Kingdom
- GERN United States
- Employees
- KNSA N/A
- GERN N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- KNSA Health Care
- GERN Health Care
- Exchange
- KNSA Nasdaq
- GERN Nasdaq
- Market Cap
- KNSA 1.6B
- GERN 1.5B
- IPO Year
- KNSA 2018
- GERN 1996
- Fundamental
- Price
- KNSA $23.09
- GERN $1.65
- Analyst Decision
- KNSA Strong Buy
- GERN Buy
- Analyst Count
- KNSA 6
- GERN 11
- Target Price
- KNSA $37.17
- GERN $5.80
- AVG Volume (30 Days)
- KNSA 684.1K
- GERN 14.9M
- Earning Date
- KNSA 04-22-2025
- GERN 05-01-2025
- Dividend Yield
- KNSA N/A
- GERN N/A
- EPS Growth
- KNSA N/A
- GERN N/A
- EPS
- KNSA N/A
- GERN N/A
- Revenue
- KNSA $423,239,000.00
- GERN $76,994,000.00
- Revenue This Year
- KNSA $37.21
- GERN $208.83
- Revenue Next Year
- KNSA $1.38
- GERN $57.49
- P/E Ratio
- KNSA N/A
- GERN N/A
- Revenue Growth
- KNSA 56.60
- GERN 32386.92
- 52 Week Low
- KNSA $16.56
- GERN $1.46
- 52 Week High
- KNSA $28.15
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- KNSA 60.12
- GERN 34.01
- Support Level
- KNSA $22.62
- GERN $1.63
- Resistance Level
- KNSA $23.42
- GERN $1.89
- Average True Range (ATR)
- KNSA 0.75
- GERN 0.11
- MACD
- KNSA -0.01
- GERN 0.04
- Stochastic Oscillator
- KNSA 68.88
- GERN 21.87
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.